Issues

VP301 is an afucosylated bispecific antibody designed with a unique structure: one arm targets the tumor-associated antigen ICAM-1, and the other arm targets CD38. This dual-targeting mechanism allows VP301 to selectively target tumor cells expressing ICAM-1 while avoiding normal cells with low CD38 expression. By precisely honing in on specific antigens, VP301 offers a targeted and selective approach to cancer therapy, minimizing impact on healthy cells. See graphical abstract and read the full article on page 127.